基因组医学通过实现个性化和基于证据的临床决策改变了癌症患者的生活。尽管取得了这些进展，但精准癌症医学的实施因其对孤立生物标志物的依赖而受到限制。批量和单细胞多组学技术的发展揭示了癌症生态系统的巨大复杂性。除了癌细胞之外，肿瘤微环境、宏观环境和宿主因素（包括微生物组）也深刻影响着癌症表型，对这些因素的解释提高了精准医疗的分辨率。强大的多组学分析和可解释的机器学习算法的出现标志着个性化癌症医学新的后基因组时代的黎明。在精准癌症医学 2.0 中，通过使用人工智能集成的肿瘤和宿主的全面多组学分析来制定高分辨率个性化临床决策。© 2024 作者。约翰·威利出版的《分子肿瘤学》

Genomic medicine has transformed the lives of patients with cancer by enabling individualised and evidence-based clinical decision-making. Despite this progress, the implementation of precision cancer medicine is limited by its dependence on isolated biomarkers. The development of bulk and single-cell multiomic technologies has revealed the enormous complexity of the cancer ecosystem. Beyond the cancer cell, the tumour microenvironment, macroenvironment and host factors, including the microbiome, profoundly influence the cancer phenotype, and accounting for these enhances the resolution of precision medicine. The advent of robust multiomic profiling and interpretable machine learning algorithms mark the dawn of a new postgenomic era of personalised cancer medicine. In Precision Cancer Medicine 2.0, high-resolution personalised clinical decision-making is informed by the comprehensive multiomic profiling of tumour and host, integrated using artificial intelligence.© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.